-
The Annals of Pharmacotherapy Jul 2016To review the use of rabbit antithymocyte globulin (rATG) induction therapy in liver transplant recipients. (Review)
Review
OBJECTIVE
To review the use of rabbit antithymocyte globulin (rATG) induction therapy in liver transplant recipients.
DATA SOURCES
A MEDLINE literature search (inception to March 2016) was conducted using the search terms rabbit antithymocyte globulin, liver transplantation, and induction References from extracted sources were further searched for any relevant, missed data sources.
STUDY SELECTION AND DATA EXTRACTION
All English-language randomized and observational studies were included.
DATA SYNTHESIS
A total of 9 studies were included in this review evaluating rATG's use for induction therapy. All studies were single-center analyses. rATG induction is utilized to delay calcineurin inhibitor initiation and to minimize or avoid steroids. Patients receiving rATG induction tended to have improved renal function compared with patients not receiving induction. Overall, rejection rates tended to be lower in recipients administered rATG. Regimens varied in each study, with most recipients receiving 2 to 3 doses of induction therapy.
CONCLUSIONS
rATG induction therapy may lead to improved renal function and lower rejection rates following liver transplant. The use of this medication can help avoid unwanted adverse effects from other immunosuppression agents. Because of the potential benefits with this induction agent, rATG may have a larger role in induction therapy for liver transplant recipients.
Topics: Animals; Antilymphocyte Serum; Female; Graft Rejection; Half-Life; Horses; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Rabbits
PubMed: 27147705
DOI: 10.1177/1060028016647974 -
Lancet (London, England) Oct 1973
Topics: Antilymphocyte Serum; Azathioprine; Humans; Immunity, Cellular; Immunosuppression Therapy; Kidney Transplantation; Prednisone; Transplantation Immunology
PubMed: 4126627
DOI: No ID Found -
[Rinsho Ketsueki] the Japanese Journal... Jan 1998
Review
Topics: Anemia, Aplastic; Animals; Antilymphocyte Serum; Cyclosporine; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy
PubMed: 9565480
DOI: No ID Found -
Leukemia & Lymphoma Sep 2008Understanding the mechanisms underlying immunological tolerance is the key to successful transplantation. Recent findings demonstrate that polyclonal antibodies such as... (Review)
Review
Understanding the mechanisms underlying immunological tolerance is the key to successful transplantation. Recent findings demonstrate that polyclonal antibodies such as the antithymocyte globulins preparations can provide wide spectrum immunomodulation, suggesting that their use in the immunosuppression therapeutic armamentarium may help in reducing the incidence of organ rejection and improving patients' outcome after hematopoietic stem cell transplantation.
Topics: Antigens, CD; Antilymphocyte Serum; Dendritic Cells; Humans; Immunosuppression Therapy; Lymphocytes
PubMed: 18798101
DOI: 10.1080/10428190802163321 -
Transplantation Proceedings Mar 1969
Topics: Animals; Antilymphocyte Serum; Dogs; Horses; Kidney Transplantation; Rabbits; Skin Transplantation; Tissue Extracts; Transplantation Immunology; Transplantation, Homologous
PubMed: 4944257
DOI: No ID Found -
Minerva Medica Jul 1970
Topics: Animals; Antilymphocyte Serum; Autoimmune Diseases; Humans; Immunosuppressive Agents; Neoplasms; Transplantation Immunology
PubMed: 5427676
DOI: No ID Found -
Transfusion 1984
Topics: Antilymphocyte Serum; Blood Transfusion; Histocompatibility Testing; Humans
PubMed: 6695445
DOI: 10.1046/j.1537-2995.1984.24184122571.x -
Experimental and Clinical... Dec 2003The induction of immunological tolerance to solid organ allograft is currently a subject of major investigation due to the morbidity and mortality related to... (Review)
Review
The induction of immunological tolerance to solid organ allograft is currently a subject of major investigation due to the morbidity and mortality related to immunosuppressive therapy. Immunosuppression induction by recipient treatment may allow to tailoring the timing and dosage of standard therapy not only reducing adverse reactions but also improving the graft outcome. Depletion of recipient T cells with polyclonal antithymocyte globulins is one of the methods nowadays investigated both in experimental and clinical procedures, demonstrating a better outcome of organ engraftment. Our intention is to give an overview of the literature about the mechanisms of action of polyclonal ATGs, the status of induction treatment in clinical and experimental transplantation as well as of the possible pathophysiological relationships with acquired tolerance, delayed graft failure and ischemia-reperfusion injury.
Topics: Animals; Antilymphocyte Serum; Humans; Immunosuppressive Agents; Organ Transplantation
PubMed: 15859913
DOI: No ID Found -
Indian Pediatrics Jun 1991
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Drug Combinations; Graft Rejection; Humans; Red-Cell Aplasia, Pure
PubMed: 1748515
DOI: No ID Found -
International Journal of Cancer Jul 1971
Topics: Animals; Antilymphocyte Serum; Mice; Neoplasm Transplantation; Polysaccharides; Sarcoma 180
PubMed: 5118210
DOI: 10.1002/ijc.2910080106